Veracyte, Inc 8-K/A, filed Feb 18, 2020
Veracyte, Inc. (VCYT)
8-K/A
2020-02-18
For: 2019-12-03
View Original
Added on
April 11, 2026
About this 8-K/A
Veracyte, Inc filed this 8-K/A on February 18, 2020, reporting on events of December 3, 2019.
Items reported
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 3, 2019
VERACYTE, INC.
(Exact name of registrant as specified in its charter)
DELAWARE | 001-36156 | 20-5455398 | ||
(State or other jurisdiction of incorporation) | Commission File Number | (IRS Employer Identification No.) | ||
6000 Shoreline Court, Suite 300, South San Francisco, California | 94080 | |
(Address of principal executive offices) | (Zip Code) | |
Registrant’s telephone number, including area code: (650) 243-6300
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, par value, $0.001 per share | VCYT | The Nasdaq Stock Market LLC | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. |
Emerging growth company o |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o |
On December 3, 2019, Veracyte, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) reporting that on December 3, 2019, the Company entered into a License and Asset Purchase Agreement with NanoString Technologies, Inc. (“NanoString”) pursuant to which the Company acquired (the “Acquisition”) a license and certain assets from NanoString. This Form 8-K/A amends the Original Form 8-K to include an audited statement of assets acquired and liabilities assumed prepared on the basis of the allocation of the Company’s purchase price as of the acquisition date (the “Abbreviated Financial Statements”) and the pro forma condensed balance sheet of the Company as of September 30, 2019, giving effect to the Acquisition. There were no liabilities assumed in connection with the Acquisition. As disclosed in the Original Form 8-K, in connection with the Acquisition, the Company obtained from the Securities and Exchange Commission, pursuant to its authority under Rule 3-13 under Regulation S-X, a waiver from the requirements of Rule 3-05 of Regulation S-X to provide certain financial statements of NanoString relating to the Acquisition, other than the Abbreviated Financial Statements.
Item 9.01 Financial Statements and Exhibits.
(a) Financial statement of business acquired. The audited statement of assets acquired and liabilities assumed is filed herewith as Exhibit 99.1. The consent of Ernst & Young, LLP, the Company’s independent registered public accounting firm, is attached as Exhibit 23.1 to this Form 8-K/A.
(b) Pro forma financial information. The unaudited pro forma condensed combined balance sheet of the Company giving effect to the Acquisition as of September 30, 2019 is filed herewith as Exhibit 99.2.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: | February 18, 2020 | ||
VERACYTE, INC. | |||
By: | /s/ Keith Kennedy | ||
Name: | Keith Kennedy | ||
Title: | Chief Operating Officer and Chief Financial Officer | ||
Exhibit 23.1
Consent of Independent Auditors
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statements (Forms S-8 Nos. 333-191992, 333-203097, 333-210185, 333-216388, 333-223292, and 333-229848) pertaining to the 2008 Stock Plan and 2013 Stock Incentive Plan of Veracyte, Inc., |
(2) | Registration Statement (Form S-8 No. 333-205206) pertaining to the Employee Stock Purchase Plan of Veracyte, Inc., and |
(3) | Registration Statements (Forms S-3 Nos. 333-204368, 333-205204, 333-224576 and 333-231153, and Form S-3/ASR No. 333-231173) of Veracyte, Inc.; |
of our report dated February 18, 2020, with respect to the Statement of Assets Acquired and Liabilities Assumed and related notes as of December 3, 2019, included in this Current Report on Form 8-K/A of Veracyte, Inc.
/s/ Ernst & Young, LLP
Redwood City, California
February 18, 2020
Exhibit 99.1
VERACYTE, INC.
STATEMENT OF ASSETS ACQUIRED AND LIABILITIES ASSUMED
TABLE OF CONTENTS
1
Report of Independent Auditors
The Board of Directors and Stockholders
Veracyte, Inc.
We have audited the accompanying Statement of Assets Acquired and Liabilities Assumed from NanoString Technologies, Inc. by Veracyte, Inc. (the “Company”) on December 3, 2019 (the Statement of Assets Acquired and Liabilities Assumed), and the related notes (collectively referred to as the “financial statement”).
Management’s Responsibility for the Statement of Assets Acquired and Liabilities Assumed
Management is responsible for the preparation and fair presentation of the financial statement in conformity with U.S. generally accepted accounting principles; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of the financial statement that is free of material misstatement, whether due to fraud or error.
Auditor’s Responsibility
Our responsibility is to express an opinion on the financial statement based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement is free of material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statement. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates, made by management, as well as evaluating the overall presentation of the financial statement.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the financial statement referred to above presents fairly, in all material respects, the assets acquired and liabilities assumed from NanoString Technologies, Inc. by Veracyte, Inc. on December 3, 2019 in conformity with U.S. generally accepted accounting principles.
Emphasis of Matter
We draw attention to Note 1 of the financial statement, which describes that the accompanying Statement of Assets Acquired and Liabilities Assumed was prepared for the purpose of complying with the rules and regulations of the Securities and Exchange Commission for inclusion in the Current Report on Form 8-K/A of Veracyte, Inc. and is not intended to be a complete presentation of the financial position of the Company. Our opinion is not modified with respect to this matter.
/s/ Ernst & Young, LLP
Redwood City California
February 18, 2020
2
VERACYTE, INC.
STATEMENT OF ASSETS ACQUIRED AND LIABILITIES ASSUMED
(in thousands)
Prosigna product technology | $ | 4,120 | |
Prosigna customer relationships | 2,430 | ||
nCounter FLEX Dx license | 46,880 | ||
LymphMark product technology | 990 | ||
Total identifiable intangible assets acquired | 54,420 | ||
Goodwill | 1,668 | ||
Assets acquired | 56,088 | ||
Liabilities assumed | — | ||
Net assets acquired and liabilities assumed | $ | 56,088 | |
The accompanying notes are an integral part of this financial statement.
3
VERACYTE, INC.
NOTES TO STATEMENT OF ASSETS ACQUIRED AND LIABILITIES ASSUMED
NOTE 1 - DESCRIPTION OF THE TRANSACTION AND BASIS OF PRESENTATION
On December 3, 2019, or Acquisition Date, Veracyte, Inc., or Company, executed an agreement, or Agreement, with NanoString Technologies, Inc., or NanoString, for (i) the exclusive global license to the nCounter FLEX Analysis System, or nCounter platform, for diagnostic use and the sale of the Prosigna and (ii) the purchase of the Prosigna Breast Cancer Prognostic Gene Signature Assay, or Prosigna, the LymphMark Lymphoma Subtyping Test, or LymphMark, and collectively with the nCounter platform and Prosigna, the assets acquired. The strategic transaction positions the Company to expand its genomic diagnostics business globally, with the ability to deliver its advanced genomic tests to physicians and their patients via hospital and clinical laboratories throughout the European Union and other parts of the world. The Company has accounted for this agreement under Accounting Standards Codification 805, Business Combinations, or ASC 805. Pursuant to the terms of the Agreement, the Company paid NanoString $40.0 million in cash and issued to NanoString $10.0 million of Company common stock, and may pay up to an additional $10.0 million in cash contingent upon the commercial launch of Company diagnostic tests for use on the platform. This contingent consideration was valued at $6.1 million as of the Acquisition Date and is included in the total consideration paid for the acquisition.
The assets acquired and liabilities assumed have not historically been accounted for separately from NanoString’s business. In addition, stand-alone full financial statements related to the assets acquired have not been prepared previously. In a letter dated November 26, 2019 from the Securities and Exchange Commission, or the SEC, the SEC stated that it would permit the substitution by the Company of an audited statement of assets acquired and liabilities assumed prepared on the basis of the allocation of the Company’s purchase price as of the Acquisition Date, or the Financial Statement, for the full historical financial statements required by Rule 3-05 of Regulation S-X under the Securities Exchange Act of 1934, as amended.
The accompanying statement of assets acquired and liabilities assumed has been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, and is not intended to be a complete presentation of the financial position of the net assets acquired on a separate standalone basis.
The Company has determined the acquired assets constitute a business acquisition as defined by ASC 805. Accordingly, the assets acquired and liabilities assumed are presented at their acquisition date fair values as required by that statement. The accounting for this acquisition is preliminary and will be finalized upon completion of the analysis of certain contracts acquired and executed as part of this acquisition and the residual impact on goodwill. Fair values are determined based on the requirements of ASC 820, Fair Value Measurements and Disclosures.
While the Company believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and the resulting amount of goodwill.
There were no liabilities assumed under the Agreement.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts on the financial statement.
Such estimates include the estimation of the fair value of intangible assets and contingent consideration. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.
Acquisitions
4
The Company first determines whether a set of assets acquired and liabilities assumed constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, the Company accounts for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective fair values as of the Acquisition Date in our financial statement. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination are recorded at fair value on the Acquisition Date and remeasured at each subsequent reporting period until the related contingencies are resolved, with the resulting changes in fair value recorded in earnings.
Finite-lived Intangible Assets
Finite-lived intangible assets consist of intangible assets acquired as part of business combinations. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of five to 15 years, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life.
Finite-lived intangible assets are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized, as follows:
Estimated Useful life (In Years) | ||
Prosigna product technology | 15 | |
Prosigna customer relationships | 5 | |
nCounter FLEX Dx license | 15 | |
LymphMark product technology | 7 | |
Goodwill
Goodwill represents the excess of the purchase price of the acquired assets over the acquisition date fair value of the net assets acquired. Goodwill is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate that it may be impaired. The Company believes the factors that contributed to goodwill include synergies that are specific to the Company's consolidated business, and not available to market participants, and the acquisition of a talented workforce that expands the Company's expertise in business development and the commercialization of its diagnostic products. As of December 31, 2019, goodwill is not deductible for tax purposes, however, if contingent consideration is paid at a future date, the portions of contingent consideration paid and allocated to the intangible assets for tax purposes will be tax deductible.
Fair Value Measurements
Financial liabilities are recorded at fair value and the contingent consideration associated with the Agreement was measured using probability-weighted analysis and is discounted using a rate that appropriately captures the risk associated with this obligation. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:
• | Level I: Inputs which include quoted prices in active markets for identical assets and liabilities; |
• | Level II: Inputs other than Level I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and |
• | Level III: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. |
The contingent consideration associated with the Agreement of $6.1 million is a Level III financial liability.
5
Acquisition-related costs
Acquisition-related costs of approximately $1.6 million were expensed as incurred by the Company during 2019.
NOTE 3 - ALLOCATION OF ACQUISITION CONSIDERATION
The statement of assets acquired and liabilities assumed is presented on the basis of the Company’s allocation of acquisition consideration. The Company accounts for business combinations under the acquisition method of accounting, which requires separately recognizing the assets acquired from goodwill assumed at their Acquisition Date fair values. The acquisition consideration has been allocated to intangible assets acquired based on estimates of their fair value. Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis of certain contracts acquired and executed as part of this acquisition and the residual impact on goodwill. While management believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired, and the resulting amount of goodwill.
The table below represents the total estimated preliminary acquisition consideration (in thousands):
Cash consideration | $ | 40,000 | |
Common stock issued (1) | 10,000 | ||
Estimated fair value of contingent consideration | 6,088 | ||
Total acquisition consideration | $ | 56,088 | |
(1) The fair value of common stock was based on an average common stock closing price of $26.54, which is not materially different from the Company's common stock closing price on December 3, 2019.
6
Exhibit 99.2
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET
The following unaudited pro forma condensed combined balance sheet is presented to give effect to the agreement with NanoString Technologies, Inc., or NanoString, for (i) the acquisition of certain assets and liabilities related to the nCounter platform, including the exclusive global license to the nCounter platform for diagnostic use and (ii) the purchase of the Prosigna Breast Cancer Prognostic Gene Signature Assay, or Prosigna, the LymphMark Lymphoma Subtyping Test, or LymphMark, and collectively with the nCounter platform and Prosigna, the Acquisition, which closed on December 3, 2019.
Veracyte, Inc., or the Company, has determined that the Acquisition constitutes a business combination as defined by Accounting Standards Codification, or ASC 805, Business Combinations. Under ASC 805, the assets acquired are recorded at their acquisition date fair values as described in the accompanying Notes to the Statement of Assets Acquired and Liabilities Assumed, in Exhibit 99.1 to this Form 8-K/A. Any excess of the purchase price over the fair value of assets acquired is recognized as goodwill. Fair values of assets acquired are determined based on the requirements of ASC 820, Fair Value Measurements and Disclosures. The fair values of assets acquired are based on the estimates of fair values as of the acquisition date included in Exhibit 99.1 to the Form 8-K/A. There were no liabilities assumed as part of the Acquisition.
The accompanying unaudited pro forma condensed combined balance sheet is based upon and derived from the historical unaudited balance sheet and related notes of the Company at September 30, 2019 included in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on October 22, 2019, as adjusted for the pro forma impact of applying the acquisition method of accounting in accordance with Generally Accepted Accounting Principles in the United States, or U.S. GAAP. As disclosed in the Original Form 8-K filed upon entering into the Acquisition agreement, the Company obtained from the Securities and Exchange Commission, pursuant to its authority under Rule 3-13 under Regulation S-X, a waiver to substitute an audited statement of assets acquired and liabilities assumed prepared on the basis of the allocation of the Company’s purchase price as of the acquisition date in lieu of the full financial statements required by Rule 3-05 of Regulation S-X. Thus, the accompanying unaudited pro forma condensed combined balance sheet at September 30, 2019 does not include the historical balances of the assets acquired from NanoString.
The pro forma adjustments are based upon available information and assumptions that the Company believes are reasonable. The allocation of purchase price reflected in this unaudited pro forma condensed combined balance sheet has been based upon estimates of the fair value of assets acquired. The pro forma adjustments have been prepared to illustrate the estimated effect of the acquisition.
The unaudited pro forma condensed combined balance sheet has been prepared to reflect the transaction as if it had occurred on September 30, 2019. The unaudited pro forma condensed combined balance sheet was prepared using the acquisition method of accounting with the Company treated as the acquiring entity. Accordingly, the aggregate value of the consideration paid by the Company to complete the Acquisition was allocated to the assets acquired based upon their estimated fair values on the closing date of the Acquisition. The Acquisition consideration has been allocated to the intangible assets acquired based on estimates of their fair value. The accounting for this acquisition is preliminary and will be finalized upon completion of the analysis of certain contracts acquired and executed as part of this acquisition and the residual impact on goodwill. While management believes that its estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and the resulting amount of goodwill.
VERACYTE, INC.
Unaudited Pro Forma Condensed Combined Balance Sheet
As of September 30, 2019
(In thousands, except share and per share amounts)
Veracyte, Inc. | Pro Forma Acquisition Adjustments | Pro Forma | |||||||||
(Unaudited) (1) | (2) | ||||||||||
Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 195,662 | $ | (40,000 | ) | $ | 155,662 | ||||
Accounts receivable | 23,613 | 23,613 | |||||||||
Supplies | 6,608 | 6,608 | |||||||||
Prepaid expenses and other current assets | 2,196 | 2,196 | |||||||||
Total current assets | 228,079 | 188,079 | |||||||||
Property and equipment, net | 8,488 | 8,488 | |||||||||
Right-of-use assets - finance lease, net | 619 | 619 | |||||||||
Right-of-use assets - operating lease | 9,033 | 9,033 | |||||||||
Finite-lived intangible assets, net | 11,200 | 54,420 | 65,620 | ||||||||
Goodwill | 1,057 | 1,668 | 2,725 | ||||||||
Restricted cash | 603 | 603 | |||||||||
Other assets | 1,228 | 1,228 | |||||||||
Total assets | $ | 260,307 | $ | 276,395 | |||||||
Liabilities and Stockholders’ Equity | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ | 5,568 | 5,568 | ||||||||
Accrued liabilities | 9,760 | 9,760 | |||||||||
Current portion of finance lease liability | 79 | 79 | |||||||||
Current portion of operating lease liability | 1,365 | 1,365 | |||||||||
Total current liabilities | 16,772 | 16,772 | |||||||||
Long-term debt | 639 | 639 | |||||||||
Acquisition related contingent consideration | — | 6,088 | 6,088 | ||||||||
Operating lease liability, net of current portion | 11,872 | 11,872 | |||||||||
Total liabilities | 29,283 | 35,371 | |||||||||
Commitments and contingencies | |||||||||||
Stockholders’ equity: | |||||||||||
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of September 30, 2019 and December 31, 2018 | — | — | |||||||||
Common stock, $0.001 par value; 125,000,000 shares authorized, 49,198,707 and 40,863,202 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively | 49 | 1 | 50 | ||||||||
Additional paid-in capital | 470,202 | 9,999 | 480,201 | ||||||||
Accumulated deficit | (239,227 | ) | (239,227 | ) | |||||||
Total stockholders’ equity | 231,024 | 241,024 | |||||||||
Total liabilities and stockholders’ equity | $ | 260,307 | $ | 276,395 | |||||||
See accompanying Notes to the Unaudited Pro Forma Condensed Combined Balance Sheet
(1) - As presented in the Company's quarterly report on Form 10-Q as at September 30, 2019 filed with the SEC on October 22, 2019.
(2) - See Note 2 to the accompanying Notes to the Unaudited Pro Forma Condensed Combined Balance Sheet
VERACYTE, INC.
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET
NOTE 1 - BASIS OF PRO FORMA PRESENTATION
The unaudited pro forma condensed balance sheet was prepared to reflect the transaction as of September 30, 2019. On December 3, 2019, the Company, executed an agreement, or Agreement, with NanoString, for the exclusive global license to the nCounter platform for diagnostic use. The unaudited pro forma condensed balance sheet was prepared as if the Agreement occurred on September 30, 2019.
The unaudited pro forma condensed balance sheet has been prepared for illustrative purposes only and is not necessarily indicative of the condensed balance sheet in future periods. The unaudited pro forma condensed balance sheet should be read in conjunction with the Company's historical condensed financial statements and related notes included in its Quarterly Report on Form 10-Q for the nine months ended September 30, 2019 filed with the SEC on October 22, 2019.
The Company expects to incur costs and realize benefits associated with integrating the assets acquired under the Agreement. The unaudited pro forma balance sheet does not reflect the costs of any integration activities or any benefits that may result from operating efficiencies or revenue synergies.
NOTE 2 - ALLOCATION OF ACQUISITION CONSIDERATION
Estimated Purchase Consideration
The table below represents the total estimated purchase price consideration (in thousands):
Cash consideration | $ | 40,000 | |
Common stock issued (1) | 10,000 | ||
Estimated fair value of contingent consideration | 6,088 | ||
Total acquisition consideration | $ | 56,088 | |
(1) Upon execution of the Agreement, the Company issued NanoString 376,732 shares of its common stock.
Allocation of Acquisition Consideration
The table below represents the preliminary allocation of purchase price to the identifiable assets acquired based on their estimated fair values, with the excess recognized as goodwill (in thousands):
Prosigna product technology | $ | 4,120 | |
Prosigna customer relationships | 2,430 | ||
nCounter FLEX Dx license | 46,880 | ||
LymphMark product technology | 990 | ||
Total identifiable intangible assets acquired | 54,420 | ||
Goodwill | 1,668 | ||
Net assets acquired | $ | 56,088 | |